| 注册
首页|期刊导航|中国药业|羟考酮预防瑞芬太尼静脉麻醉术后痛觉过敏临床研究

羟考酮预防瑞芬太尼静脉麻醉术后痛觉过敏临床研究

胡春欢 张琦 柴方圆 刘书宇

中国药业2017,Vol.26Issue(14):32-34,3.
中国药业2017,Vol.26Issue(14):32-34,3.DOI:10.3969/j.issn.1006-4931.2017.14.011

羟考酮预防瑞芬太尼静脉麻醉术后痛觉过敏临床研究

Clinical Study of Oxycodone for Prventing Hyperalgesia After Remifentanil Intravenous Anesthesia

胡春欢 1张琦 1柴方圆 1刘书宇2

作者信息

  • 1. 牡丹江医学院第二附属医院麻醉科,黑龙江 牡丹江 304339
  • 2. 牡丹江医学院红旗医院医学影像科,黑龙江 牡丹江 304339
  • 折叠

摘要

Abstract

Objective To investigate the clinical effect of oxycodone for prventing postoperative hyperalgesia after remifentanil intravenous anesthesia. Methods Totally 68 patients treated with remifentanil intravenous anesthesia admitted to our hospital in 2016 were randomly divided into the two groups. During operation,the two groups were given Remifentanil intravenous infusion for maintenance anesthesia. 10 min before the end of the operation,patients in the control group and the observation group were given fentanyl and oxycodone for preventing postoperative hyperalgesia. The postoperative recovery,VAS score and adverse reactions were compared between the two groups. Results The spontaneous breathing recovery time,postoperative recovery time and laryngeal mask extraction time in the observa-tion group were significantly shorter than those in the control group( P < 0. 05),The VAS scores at laryngeal mask was removed and 30 min after it was removed in the observation group were significantly lower than those in the control group ( P < 0. 05),the inci-dence rate of adverse reactions in the observation group was 5. 88%,which was lower than 11. 76% in the control group,but the dif-ference was not significant( P > 0. 05). Conclusion The clinical effect of oxycodone for prventing postoperative hyperalgesia after remifentanil intravenous anesthesiais is good,with less adverse reactions,it is worthy of clinical promotion.

关键词

羟考酮/瑞芬太尼/痛觉过敏/静脉麻醉

Key words

oxycodone/rremifentanil/hyperalgesia/intravenous anesthesia

分类

医药卫生

引用本文复制引用

胡春欢,张琦,柴方圆,刘书宇..羟考酮预防瑞芬太尼静脉麻醉术后痛觉过敏临床研究[J].中国药业,2017,26(14):32-34,3.

中国药业

OACSTPCD

1006-4931

访问量0
|
下载量0
段落导航相关论文